New Science Ventures
Investor profile
Deals
10
distinct rounds
Companies
7
backed
Active span
2009–2022
14 yrs
Total round €
€296M
sum of rounds joined
Deals by year
distinct rounds / yearTop sectors
by dealsStages
by dealsCountries
by dealsCo-investment network
shared roundsHover a node for shared-deal counts; click a co-investor to open its profile.
Frequent co-investors
shared rounds- Bpifrance2
- CR-CP Life Science Fund2
- Financière Fonds Privés2
- FundPlus2
- InvestSud2
- SRIW Life Sciences2
- Syncona Partners2
- VIVES Louvain Technology Fund2
- Amadeus Capital Partners1
- BGV1
- British Patient Capital’s “Future Fund: Breakthrough”1
- Cambridge Enterprise1
- Capnamic Ventures1
- CEA Investissement1
- CEA Investment1
- Dynalim1
- Forbion1
- Forbion Growth1
- GV (Google Ventures)1
- HERE1
- In-Q-Tel1
- Innoven Partners1
- Integrated Systems Development1
- Invest.BW1
- IQ Capital1
Portfolio
top 30 by total round €| Company | Country | Rounds | Total € |
|---|---|---|---|
| Northsea Therapeutics | Netherlands | 1 | €71M |
| Novadip Biosciences | Belgium | 2 | €59M |
| Paragraf | UK | 1 | €54M |
| ISORG | France | 2 | €40M |
| BioVex | UK | 1 | €36M |
| Cambridge Epigenetix | UK | 2 | €24M |
| Zeotap | Germany | 1 | €12M |
Biggest deals
top 10 by amount| Company | Stage | Amount | Date |
|---|---|---|---|
| Northsea Therapeutics | Other | €71M | 2021-12 |
| Paragraf | Series B | €54M | 2022-03 |
| Novadip Biosciences | Series B | €40M | 2022-11 |
| BioVex | Series D+ | €36M | 2009-02 |
| ISORG | Series B | €24M | 2018-09 |
| Cambridge Epigenetix | Series B | €19M | 2016-02 |
| Novadip Biosciences | Series B | €19M | 2021-11 |
| ISORG | Series C | €16M | 2021-07 |
| Zeotap | Series B | €12M | 2016-12 |
| Cambridge Epigenetix | Series A | €5.0M | 2014-09 |